Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28108614 | 0.89 | TSHR (0.55) | KMT2AHSD17B10LMNATDP1MEN1 | |
| SCHEMBL10894554 | 0.87 | TSHR (0.48) | KMT2AHSD17B10TDP1MEN1TSHR | |
| SCHEMBL25749262 | 0.82 | KMT2A (0.50) | KMT2AHSD17B10LMNATDP1MEN1 | |
| SCHEMBL17633836 | 0.82 | MEN1 (0.54) | KMT2AHSD17B10TDP1MEN1TSHR | |
| SCHEMBL16573662 | 0.81 | MEN1 (0.45) | KMT2AHSD17B10MEN1TSHRGBA1 | |
| SCHEMBL17752144 | 0.81 | GBA1 (0.50) | KMT2AHSD17B10MEN1TSHRGBA1 | |
| SCHEMBL24714503 | 0.80 | ALDH1A1 (0.42) | KMT2AHSD17B10LMNATDP1MEN1 | |
| SCHEMBL14241913 | 0.79 | MEN1 (0.56) | KMT2AHSD17B10MEN1TSHRGBA1 | |
| SCHEMBL1709332 | 0.79 | MEN1 (0.61) | KMT2AMEN1TSHRECE1RECQL | |
| SCHEMBL16573671 | 0.79 | TSHR (0.50) | KMT2AHSD17B10MEN1TSHRGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | ERBB3, ERBB2, PANK2 | KMT2A 3022/4885HSD17B10 2690/4885LMNA 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.